ArticleCancer communications (London, England)2021

Real-world outcomes of ibrutinib therapy in Korean patients with relapsed or refractory mantle cell lymphoma: a multicenter, retrospective analysis.

Jun Ho Yi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.